Case Report: LDAC for the Treatment of Post-Splenectomy Newly Diagnosed PMF Patent with Oral Treatment Inability

Harutyunyan L; Meliksetyan K; Oganesyan A; Oseyan H; Khachatryan H; Hakobyan Y

Abstract

Case Report: LDAC for the Treatment of Post-Splenectomy Newly Diagnosed PMF Patent with Oral Treatment Inability

Primary myelofibrosis (PMF) is a hematologic malignancy belonging to Ph negative myeloproliferative neoplasms (MPN), and it is commonly characterized by a higher risk of acute myeloid leukemia (AML) transformation. The aim of this case report is a demonstration of treatment with low dose cytarabine (LDAC) for a non-transformed newly diagnosed PMF patient with the inability of oral therapy and post-splenectomy complications.

Author(s):

Harutyunyan L, Meliksetyan K, Oganesyan A, Oseyan H, Khachatryan H and Hakobyan Y

Abstract | Full-Text | PDF

Share this